Abstract
Due to the presence of the blood-brain barrier, there is limited drug access into the brain. In order to overcome this challenge, various strategies have been developed to enhance penetration of drugs into the brain. Of these, the most frequently used are pharmacological technologies or comparable methods being developed for brain-targeting drug delivery using receptor- or adsorptive- or transporter-mediated transcytosis and the nose-to-brain route. It goes without saying that exploration of Brain-targeting drug delivery systems has created another potential option for the treatment of central nervous system diseases. In addition to above methods, other technologies for brain-targeting drug delivery (e.g. chemical delivery systems, prodrugs, pharmacological disruption of the BBB and inhibition of drug efflux by P-glycoprotein) are also summaried in this review.
Keywords: Blood-brain barrier, brain-targeting drug delivery systems, receptor-mediated transcytosis, adsorptive-mediated transcytosis, transporter-mediated transcytosis, nose-to-brain, chemical delivery systems, prodrugs, P-glycoprotein, Targeting drug delivery, colloidal drug, harmful blood-borne substances, small molecule drugs, endothelium cells
Current Pharmaceutical Biotechnology
Title:Perspectives on Brain-Targeting Drug Delivery Systems
Volume: 13 Issue: 12
Author(s): Liangran Guo, Jinfeng Ren and Xinguo Jiang
Affiliation:
Keywords: Blood-brain barrier, brain-targeting drug delivery systems, receptor-mediated transcytosis, adsorptive-mediated transcytosis, transporter-mediated transcytosis, nose-to-brain, chemical delivery systems, prodrugs, P-glycoprotein, Targeting drug delivery, colloidal drug, harmful blood-borne substances, small molecule drugs, endothelium cells
Abstract: Due to the presence of the blood-brain barrier, there is limited drug access into the brain. In order to overcome this challenge, various strategies have been developed to enhance penetration of drugs into the brain. Of these, the most frequently used are pharmacological technologies or comparable methods being developed for brain-targeting drug delivery using receptor- or adsorptive- or transporter-mediated transcytosis and the nose-to-brain route. It goes without saying that exploration of Brain-targeting drug delivery systems has created another potential option for the treatment of central nervous system diseases. In addition to above methods, other technologies for brain-targeting drug delivery (e.g. chemical delivery systems, prodrugs, pharmacological disruption of the BBB and inhibition of drug efflux by P-glycoprotein) are also summaried in this review.
Export Options
About this article
Cite this article as:
Guo Liangran, Ren Jinfeng and Jiang Xinguo, Perspectives on Brain-Targeting Drug Delivery Systems, Current Pharmaceutical Biotechnology 2012; 13 (12) . https://dx.doi.org/10.2174/138920112803341770
DOI https://dx.doi.org/10.2174/138920112803341770 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Selective Pharmacological Inhibition of the Pacemaker Channel Isoforms (HCN1-4) as New Possible Therapeutical Targets
Current Medicinal Chemistry NO Chimeras as Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research Non-Respiratory Manifestations of COVID-19 and Pathophysiological Evidences
New Emirates Medical Journal Eidtorial from Editor-in-Chief : [ Keeping up with Advances in Cardiovascular and Hematological Medicine in 2012 ]
Cardiovascular & Hematological Agents in Medicinal Chemistry Drug Discovery and Design for Complex Diseases through QSAR Computational Methods
Current Pharmaceutical Design Bombacaceae Between the Ethnomedical Uses and Pharmacological Evidences: A Review
The Natural Products Journal A Review of Voltammetric Methods for Determination of Dopamine Agonists
Current Analytical Chemistry Anti-hypertensive Effects of Diminazene Aceturate: An Angiotensin- Converting Enzyme 2 Activator in Rats
Protein & Peptide Letters New Insights for Multifactorial Disease Therapy: The Challenge of the Symbiotic Drugs
Current Drug Therapy Dose Related Patterns of Ventricular Arrhythmia due to Carvedilol Withdrawal in Patients with Systolic Heart Failure
Current Drug Safety The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology Autoimmune Channelopathies of the Nervous System
Current Neuropharmacology Potential Effect of Angiotensin II Receptor Blockade in Adipose Tissue and Bone
Current Pharmaceutical Design Ethyl Pyruvate: A Novel Treatment for Sepsis
Current Drug Targets A Role for Leptin in the Systemic Inflammatory Response Syndrome (SIRS) and in Immune Response, an Update
Current Medicinal Chemistry Efficacy and Safety of Nonopioid Analgesics in Perioperative Pain Control
Current Drug Safety An Overview of Olive Oil Biomolecules
Current Biotechnology Corticotropin Releasing Factor (CRF) Peptide Family and their Receptors: Divergent Actions Influencing Human Physiology
Current Genomics Ebola and Marburg Viruses: Pathogenesis and Development of Countermeasures
Current Molecular Medicine Revisiting the J-curve Phenomenon. An Old New Concept?
Current Hypertension Reviews